- Home
- LRMR
as 07-08-2024 4:00pm EST
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BALA CYNWYD |
| Market Cap: | 462.6M | IPO Year: | N/A |
| Target Price: | $21.33 | AVG Volume (30 days): | 622.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.18 - $13.68 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Larimar Therapeutics Inc. (LRMR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hamilton Thomas Edward | LRMR | Director | Feb 16 '24 | Buy | $8.74 | 57,208 | $499,997.92 | 564,798 | SEC Form 4 |
| Flynn James E | LRMR | Director10% Owner | Feb 16 '24 | Buy | $8.74 | 1,430,206 | $12,500,000.44 | 6,151,389 | SEC Form 4 |
| Flynn James E | LRMR | Director10% Owner | Feb 16 '24 | Buy | $8.74 | 1,430,206 | $12,500,000.44 | 6,151,406 | SEC Form 4 |
| Flynn James E | LRMR | Director10% Owner | Feb 16 '24 | Buy | $8.74 | 1,430,205 | $12,499,991.70 | 4,207,982 | SEC Form 4 |
| THOMAS FRANK E | LRMR | Director | Feb 14 '24 | Buy | $11.00 | 2,000 | $22,000.00 | 2,000 | SEC Form 4 |
| Shankar Gopi | LRMR | Chief Development Officer | Dec 7 '23 | Buy | $3.73 | 5,000 | $18,661.50 | 5,000 | SEC Form 4 |
Latest Larimar Therapeutics Inc. News
LRMR Breaking Stock News: Dive into LRMR Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
GlobeNewswire
2 months ago
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
Simply Wall St.
2 months ago
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
GlobeNewswire
2 months ago
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
GuruFocus.com
4 months ago
Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results
GlobeNewswire
4 months ago
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
GlobeNewswire
4 months ago
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
GlobeNewswire
4 months ago
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Share on Social Networks:
Disclaimer
The information presented on this page, "LRMR Larimar Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.